Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas is viewed favorably because the VEPPANU partnership with Rigel, alongside $85M upfront and up to $320M in milestones and split royalties, removes a major commercial overhang and lets management redeploy capital into the wholly owned pipeline. The company also appears financially resilient, with cash runway into 2H28 and stock trading near cash and near zero EV, which provides downside protection while investors wait for clinical catalysts over the next 12-18 mos. Fundamentally, the bull case is supported by differentiated degrader science across oncology and neuroscience, including ARV-102’s >50% CSF LRRK2 degradation at all doses by day 14 with a clean safety profile and ARV-6723’s planned phase 1 initiation in mid-2026.

Arvinas is facing a fundamentally fragile risk profile because its value depends on clinical and regulatory success for a small set of unproven degraders, and unfavorable data or an FDA rejection could stop development entirely. The company also depends on third-party CMOs for manufacturing, faces meaningful competition in breast cancer and protein degradation, and remains exposed to patent challenges that could limit long-term market potential. Financially, it still needs reliable external funding to advance assets through trials, while ARV-806’s upcoming phase 1 readout hinges on early safety and efficacy signals rather than durable proof, underscoring how far the pipeline remains from de-risked commercialization.